AR017172A1 - Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden - Google Patents
Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR017172A1 AR017172A1 ARP980104976A ARP980104976A AR017172A1 AR 017172 A1 AR017172 A1 AR 017172A1 AR P980104976 A ARP980104976 A AR P980104976A AR P980104976 A ARP980104976 A AR P980104976A AR 017172 A1 AR017172 A1 AR 017172A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- lower alkyl
- radical
- alkyl radical
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
Abstract
Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona que responden a la siguiente formula (I) general, en donde: R representa: un radical alquiloinferior que tiene de 1 a 6 átomos de carbono; un radical haloalquilo inferior que tiene de 1 a 6átomos de carbono, o un grupo -NH2, R1 representa: un átomode hidrogeno, un radical alquilo inferior que tiene de 1 a 6 átomos de carbono o un radical haloalquilo inferior que tiene de 1 a 6 átomos de carbono, Xrepresenta: un átomo de oxígeno, o un átomo de azufre, X1 y X2 independientemente representan: un átomo de hidrogeno, un átomo de halogeno, un radical alquiloinferior que tiene de 1 a 6 átomos de carbono, un radical haloalquilo inferior que tiene de 1 a 6 átomos de carbono, un radical O-alquilo inferior que tiene de1 a 6 átomos de carbono, un radical NR2R3 en donde R2 y R3 independientemente representan un radical alquilo inferior que tiene de 1 a 6 átomos de carbono, oinclusive X1 y X2 juntas pueden formar un grupo dioximetileno, así como sus sales de adicion en particular las sales de adicion farmacéuticamente aceptablescuando X1 y X2 tienen una funcion salificable. Un método para la preparacion de tales derivados y composiciones farmacéuticas que los comprenden. Estoscompuestos poseen propiedades antiinflamatorias y analgésicas siendo bien tolerados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9712459A FR2769311B1 (fr) | 1997-10-07 | 1997-10-07 | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
AR017172A1 true AR017172A1 (es) | 2001-08-22 |
Family
ID=9511893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104976A AR017172A1 (es) | 1997-10-07 | 1998-10-06 | Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden |
Country Status (12)
Country | Link |
---|---|
US (1) | US5859036A (es) |
EP (1) | EP1023277A1 (es) |
JP (1) | JP2001519343A (es) |
AR (1) | AR017172A1 (es) |
AU (1) | AU747221B2 (es) |
CA (1) | CA2306245A1 (es) |
CO (1) | CO4980887A1 (es) |
FR (1) | FR2769311B1 (es) |
PE (1) | PE120099A1 (es) |
TW (1) | TW520365B (es) |
WO (1) | WO1999018093A1 (es) |
ZA (1) | ZA988921B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
ES2236007T3 (es) * | 1999-12-08 | 2005-07-16 | Pharmacia Corporation | Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido. |
JP2003531202A (ja) * | 2000-04-25 | 2003-10-21 | ファルマシア・コーポレーション | 3,4−ジ(カルボシクリルまたはヘテロシクリル)チオフェンの位置選択的合成 |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
AU5754701A (en) * | 2000-07-13 | 2002-01-30 | Pharmacia Corp | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
EP1363669A2 (en) * | 2001-02-02 | 2003-11-26 | Pharmacia Corporation | Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
US7695736B2 (en) | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
KR100804827B1 (ko) * | 2002-05-17 | 2008-02-20 | 씨제이제일제당 (주) | 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물 |
KR100465455B1 (ko) * | 2002-06-24 | 2005-01-13 | 씨제이 주식회사 | 2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
CN1309717C (zh) * | 2003-06-03 | 2007-04-11 | 李小虎 | 4-芳基-5h-噻吩-2-酮衍生物、其制法和用途 |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2050439A1 (de) * | 1970-10-14 | 1972-04-20 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Thiazolon-(2)-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
CA2276945C (en) * | 1993-11-30 | 2006-08-01 | G.D. Searle & Co. | Tricyclic-substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions thereof |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
-
1997
- 1997-10-07 FR FR9712459A patent/FR2769311B1/fr not_active Expired - Fee Related
- 1997-10-31 US US08/962,256 patent/US5859036A/en not_active Expired - Lifetime
-
1998
- 1998-09-09 TW TW087114980A patent/TW520365B/zh active
- 1998-09-28 CO CO98056357A patent/CO4980887A1/es unknown
- 1998-09-28 PE PE1998000920A patent/PE120099A1/es not_active Application Discontinuation
- 1998-09-30 ZA ZA988921A patent/ZA988921B/xx unknown
- 1998-10-06 JP JP2000514904A patent/JP2001519343A/ja active Pending
- 1998-10-06 WO PCT/FR1998/002128 patent/WO1999018093A1/fr not_active Application Discontinuation
- 1998-10-06 EP EP98947607A patent/EP1023277A1/fr not_active Withdrawn
- 1998-10-06 AU AU94462/98A patent/AU747221B2/en not_active Ceased
- 1998-10-06 AR ARP980104976A patent/AR017172A1/es unknown
- 1998-10-06 CA CA002306245A patent/CA2306245A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO4980887A1 (es) | 2000-11-27 |
AU747221B2 (en) | 2002-05-09 |
CA2306245A1 (en) | 1999-04-15 |
WO1999018093A1 (fr) | 1999-04-15 |
EP1023277A1 (fr) | 2000-08-02 |
FR2769311B1 (fr) | 1999-12-24 |
US5859036A (en) | 1999-01-12 |
AU9446298A (en) | 1999-04-27 |
ZA988921B (en) | 1999-04-12 |
TW520365B (en) | 2003-02-11 |
PE120099A1 (es) | 1999-12-19 |
JP2001519343A (ja) | 2001-10-23 |
FR2769311A1 (fr) | 1999-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR017172A1 (es) | Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden | |
BR9912937A (pt) | Pró-drogas de inibidores de bomba de prótons | |
HUP9901074A2 (hu) | Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
CY1110240T1 (el) | Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ES2159922T3 (es) | Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
PT1233953E (pt) | Novos derivados de benzotiadiazinas processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
AR013608A1 (es) | Derivados de 3,4-diariloxazolona, procedimiento para su preparacion, y composicion farmaceutica que los comprende. | |
DK0952159T3 (da) | Anvendelse af phenylhydrazonderivater som antiinflammatoriske eller analgetiske midler | |
EA200101230A1 (ru) | Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции | |
AR006301A1 (es) | Derivados de oxazolidin-2-ona, procedimiento para prepararlos, medicamento constituido por dicho derivado y composicion farmaceutica que comprende a dicho derivado | |
ATE214051T1 (de) | Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
ATE214064T1 (de) | Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
DK0913151T3 (da) | Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel | |
DE60312953D1 (de) | Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol | |
YU48094B (sh) | Derivati fenoksietilamina i postupak za njihovo dobijanje | |
ES2065192T3 (es) | Nuevos nicotinatos de diacil-glicerol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
EA200100155A3 (ru) | Новые производные 6-амино или 6-гидразиносульфонил-3-хинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции | |
DE3860117D1 (de) | 2,3-dihydro-3-phenyl-benzofuran-2-on-acetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
NO974598D0 (no) | Fenoksyetylaminderivater med höy affinitet til 5-HT1A-reseptoren, fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende nevnte derivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |